How has the FDA's recent decisions on rare disease drugs affected investment trends? Why is Eli Lilly getting into sleep medicine? Find out on this week's episode of "The Readout…
STAT+: NIH would get $5 billion cut under Trump’s 2027 budget, but Congress unlikely to go along
The White House is asking Congress to cut $5 billion from the National Institutes of Health and to downsize the number of its institutes and centers from 27 to 22 — a plan that is expected to receive a chilly reception from lawmakers from…
Opinion: ‘Medical nutrition’ helps keep my son, and many others, healthy. But insurance won’t cover it
My son is now in high school, but when he was in the second grade, I received a call that changed everything: “We think he had a stroke.” He had developed a facial droop and couldn’t walk on his own. His teacher carried him to the nurse’s…
STAT+: UnitedHealth Group is making a $3 billion bet on AI. What does it mean for patients?
From a scan of its job openings, it would be easy to mistake UnitedHealth Group for Silicon Valley’s latest artificial intelligence juggernaut. Hundreds of postings seek applicants with expertise in data science and artificial…
STAT+: How a four-month FDA delay forced a small biotech company to close its doors
In February, a small biotech company called Kezar Life Sciences reached a breakthrough with the Food and Drug Administration, agreeing to a plan for a clinical trial it hoped could lead to the approval of its treatment for a rare,…
What the peptide craze reveals about Americans’ relationship with risk
Robert F. Kennedy Jr. tends to favor health choices he sees as natural — whether that means eating “real food” like meat and vegetables instead of ultra-processed food or suggesting, falsely, that nutrition and vitamins are a good…
Opinion: When my child is in psychosis, the pediatric health care system can’t help us
I am sitting in a firm recliner with a wipeable surface during a two-day hospital admission for testing at our local children’s hospital. The chair is designed for durability, not sleep. The pillow beneath my head is flat and smells…
STAT+: Neurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal
Neurocrine Biosciences said Monday that it would buy Soleno Therapeutics and its treatment for Prader-Willi syndrome for $2.9 billion. Neurocrine is paying $53 a share for Soleno, a 34% premium to its closing price on Thursday. Soleno’s…
UnitedHealth makes a bet on AI. What does it mean for us?
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. You have until 9 pm ET tonight to vote in the final round of STAT Madness! Make your voice heard, and then…